BioNTech SE (FRA:22UA)
Germany · Delayed Price · Currency is EUR 78.05
-2.50 (-3.10%)
At close: Oct 23, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€339,439
Profits / Employee
€216,011
Market Cap
19.77B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,486 |
| Fresenius Medical Care AG | 107,226 |
| Bayer Aktiengesellschaft | 87,830 |
| Siemens Healthineers AG | 74,300 |
| Merck KGaA | 62,136 |
| Fielmann Group AG | 18,928 |
| Sartorius Aktiengesellschaft | 14,279 |
| Ottobock SE & Co. KGaA | 9,406 |
BioNTech SE News
- 5 hours ago - BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial - TheFly
- 18 hours ago - BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy - GlobeNewsWire
- 2 days ago - Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street? - TipRanks
- 3 days ago - BioNTech, Gilead to test drug combination in advanced breast cancer trial - Reuters
- 3 days ago - BioNTech announces collaboration, supply agreement with Gilead - TheFly
- 3 days ago - BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer - GlobeNewsWire
- 5 days ago - BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 - GlobeNewsWire
- 6 days ago - BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 - GlobeNewsWire